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Ifosfamide and cisplatin cause urinary loss of carnitine, which is a fundamental molecule for energy production in mammalian
cells. We investigated whether restoration of the carnitine pool might improve chemotherapy-induced fatigue in non-anaemic
cancer patients. Consecutive patients with low plasma carnitine levels who experienced fatigue during chemotherapy were
considered eligible for study entry. Patients were excluded if they had anaemia or other conditions thought to be causing
asthenia. Fatigue was assessed by the Functional Assessment of Cancer Therapy-Fatigue quality of life questionnaire. Treatment
consisted of oral levocarnitine 4 g daily, for 7 days. Fifty patients were enrolled; chemotherapy was cisplatin-based in 44
patients and ifosfamide-based in six patients. In the whole group, baseline mean Functional Assessment of Cancer Therapy-
Fatigue score was 19.7 (+6.4; standard deviation) and the mean plasma carnitine value was 20.9 mM (+6.8; standard
deviation). After 1 week, fatigue ameliorated in 45 patients and the mean Functional Assessment of Cancer Therapy-Fatigue
score was 34.9 (+5.4; standard deviation) (P5.001). All patients achieved normal plasma carnitine levels. Patients maintained
the improved Functional Assessment of Cancer Therapy-Fatigue score until the next cycle of chemotherapy. In selected
patients, levocarnitine supplementation may be effective in alleviating chemotherapy-induced fatigue. This compound deserves
further investigations in a randomised, placebo-controlled study.
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In cancer patients, increasing attention is being devoted to the assess-
ment and management of fatigue (Richardson and Ream, 1996; Stone
et al, 2000). Fatigue is a common symptom in patients with advanced
disease, and it is frequently reported as a side-effect of chemotherapy
(Richardson and Ream, 1996; Morrow et al, 1999; Stone et al, 2000).
Cancer-related fatigue causes a dramatic impairment of the physical
status, but it is often underestimated and poorly managed by physi-
cians (Stone et al, 2000). Physiological factors (anaemia, metabolic
abnormalities, malnourishment), psychological factors (depression,
sleep deprivation) or tumour-related factors (altered metabolic func-
tions, cytokines) are among the known etiologies that contribute to
fatigue (Portenoy and Itri, 1999). Many patients report fatigue a
few days after their ﬁrst chemotherapy treatment (Richardson and
Ream, 1996; Morrow et al, 1999), but this early presentation is often
unexplained by common predisposing factors or other evident
underlying conditions (Portenoy and Itri, 1999; Schwartz et al, 2000).
In light of recent biochemical investigations, it is possible that
carnitine deﬁciency may have a role in the development of
chemotherapy-induced fatigue (Dodson et al, 1989; Breitkreutz et
al, 2000; Peluso et al, 2000). In humans, carnitine derives from food
intake or biosynthesis from the metabolism of lysine and methionine.
Carnitine is produced in liver and kidneys, stored in skeletal muscle,
and excreted mainly in urine. In mammalian cells, carnitine and its
products play a central role in the energy metabolism. Carnitine is
indispensable for glucose and lipid turnover, and it is essential for
mitochondrial fatty acid oxidation, which is the primary fuel source
in heart and skeletal muscle (Peluso et al, 2000). Chemotherapy
causes dysfunction of the carnitine system, which may contribute
to a condition of asthenia due to the impaired energy metabolism
(Breitkreutz et al, 2000; Peluso et al, 2000). Ifosfamide and cisplatin
alter major enzymatic pathways and they cause carnitine secondary
deﬁciency after increasing urinary excretion of the molecule (Dodson
et al, 1989; Heuberger et al, 1998; Marthaler et al, 1999).
Levocarnitine (LC) supplementation was found to restore normal
plasma carnitine levels and resolve symptomatic deﬁciencies with
excellent tolerability to treatment (Baker et al, 1993). In haemodialy-
sis patients, LC treatment increased plasma carnitine concentrations
and improved patient-assessed fatigue (Brass et al, 2001).
On this basis, we investigated whether LC supplementation may
have a role in ameliorating chemotherapy-induced fatigue in non-
anaemic patients with solid tumours.
MATERIALS AND METHODS
Patients
Consecutive patients with solid tumours who experienced fatigue
during ﬁrst-line, palliative chemotherapy containing ifosfamide or
cisplatin were considered eligible for study entry. Inclusion criteria
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and liver functions; adequate bone marrow reserve with haemoglo-
bin (Hb) level 513 g/dl; low plasma level of free carnitine
(530 mM). Also, adequate dietary/caloric intake (30–40 Kcal Kg
day
71) and normal Body Mass Index (19–24 Kg h
2) were evalu-
ated by dietician consultants before study entry. Patients
receiving corticosteroids, psychostimulants or vitamins and patients
with anaemia or other underlying conditions associated with asth-
enia were excluded. The protocol was approved by each local
institutional review board and all patients gave written informed
consent.
Fatigue assessment
Assessments of fatigue were performed using the Italian version of
the Functional Assessment of Cancer Therapy-Fatigue (FACT-F)
quality of life questionnaire (Yellen et al, 1997). This 13-item scale
is a tool for the ad hoc measurement of fatigue and its inﬂuence on
global quality of life of cancer patients. Each question is scored on
a ﬁve-point scale rating from 0 (not at all) to 4 (very much). The
FACT-F investigates fatigue symptoms over a 7-day period and
lower FACT-F scores are associated with higher levels of fatigue.
The FACIT scales are designed for patient self-administration or
interview format. In this study, an investigator was trained at each
Institution so as to elicit non-biased patient responses. During the
interviews, patients held a card on which the response options were
printed.
Treatment plan with LC
According to the current knowledge of the carnitine system, its
metabolism and treatment of deﬁciency, a high daily fractioned
dose of LC for 7 days was chosen for this study. The dosage was
spaced throughout the day (every 12 h), preferably during or
following meals. It was found that daily administrations of 2–3
g of LC led to blood carnitine concentrations superior to normal
levels (Bach et al, 1983; Baker et al, 1993; Brass et al, 2001). Rapid
recovery of symptomatic plasma carnitine deﬁciency is obtained
within 10 days by either oral high-dose treatment (3–4 g) in a
single administration or by more prolonged therapy (Bizzi et al,
1978; Campos et al, 1993). Mucosal absoption of LC is saturated
by 2 g doses and oral fractioned treatment for higher doses is
required (Farper et al, 1988).
Study design
Enrolled patients completed the baseline FACT-F questionnaire and
supplied blood samples to determine their plasma levels of free
carnitine (Deufel, 1990; Xia and Folkers, 1991). In the general popu-
lation this value is reported as 430 mM (Deufel, 1990; Xia and
Folkers, 1991) and in a preliminary analysis in 30 healthy subjects
we found a mean value of 40.5 mM (s.d.; 33–48). After baseline
evaluation, patients started treatment with oral LC 2 g solution
B.I.D., for 7 days (Sigma Tau S.p.A., Rome, Italy). During treat-
ment, patients were monitored weekly with physical examination,
medical history, blood chemistries and FACT-F assessments until
the next cycle of chemotherapy. Tumour response was evaluated
according to the World Health Organisation criteria (WHO, 1979).
In this study, values were reported as means+standard devia-
tion (s.d.). Differences in means between two or more groups
were analysed using two-tailed Student’s t-test or one-way ANOVA
(Instat 3.0. GraphPad Software Inc, San Diego CA, USA). Values of
P50.05 were considered statistically signiﬁcant.
RESULTS
Between December 1999 and March 2001, 50 patients were
enrolled in this prospective study. They were fully evaluable for
the outcome analysis of LC supplementation and their characteris-
tics are reported in Table 1. All patients received combination
chemotherapy for palliative treatment of stage IV solid tumours.
It was cisplatin-based in 20 patients with non-small cell lung
cancer, 16 patients with gastric cancer, four patients with small-cell
lung cancer, four patients with ovarian cancer and two patients
with pancreatic cancer. It was ifosfamide-based in four patients
with soft-tissue sarcomas. Fatigue was complained of after the ﬁrst
cycle of chemotherapy in 20 patients and after the second cycle in
30 patients. In the 50 patients, baseline mean Hb level was
13.6 g dl
71 (+0.5; s.d.), mean FACT-F score was 19.7 (+6.4;
s.d.) and the mean plasma carnitine value was 20.9 mM (+6.8;
s.d.).
All the 50 patients received the planned treatment without LC
dose reductions and each patient completed three follow-up
FACT-F questionnaires. After 1 week, 50 patients showed post-
treatment plasma levels of free carnitine 430 mM and fatigue
ameliorated in 45 patients (90%). In Table 2 mean FACT-F
scores and mean haemoglobin levels at baseline (before starting
LC) and subsequent weekly assessments are shown. The mean
FACT-F scores after 1, 2 and 3 weeks following the baseline
evaluation were: 34.9 (+5.4; s.d.), 35.7 (+5.5; s.d.) and 36.5
(+5.1; s.d.), respectively. The difference in FACT-F mean values
between the baseline and the ﬁrst post-treatment assessment was
statistically signiﬁcant (P5.001). Differences in post-treatment
FACT-F assessments between the ﬁrst and the second week,
and between the second and the third week were not statistically
signiﬁcant (P40.05). In the ﬁve non-responder patients, FACT-F
scores remained stable in three patients and worsened in two
patients.
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Table 1 Characteristics of the 50 patients enrolled in the study
Number of patients 50
Sex ratio
Male 30
Female 20
Median age years (range) 61 (45–70)
ECOG Performance status
03 1
I1 9
Chemotherapy
Cisplatin/gemcitabine 22
Cisplatin/epirubicin/ﬂuorouracil 16
Cisplatin/etoposide 4
Cisplatin/taxol 4
Ifosfamide/adriamycin 4
Per cent response rate to chemotherapy
non small cell lung cancer 44
gastric cancer 39
other 25
Timing of fatigue perception
After 1 cycle 20
After 2 cycles 30
Table 2 Variation of FACT-F and hemoglobin values in the 50 patients
Timing Mean FACT-F (s.d.) Mean Hb g dL
71 (s.d.)
Baseline 19.7 (+6.4) 13.6 (+0.6)
P50.001 P40.05
After 1 week 34.9 (+5.4) 13.4 (+0.5)
P40.05 P40.05
After 2 weeks 35.7 (+5.5) 13.0 (+0.3)
P40.05 P40.05
After 3 weeks 36.5 (+5.1) 13.2 (+0.5)
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In mammalian cells, the carnitine system is essential for glucose
and lipid turnover and it plays a crucial role in maintaining the
energy metabolism (Breitkreutz et al, 2000; Peluso et al, 2000).
Chemotherapy causes dysfunction of enzymes involved in the
transport and trafﬁcking of carnitines (Peluso et al, 2000) and, in
addition, ifosfamide and cisplatin induce increased urinary excre-
tion of these molecules (Dodson et al, 1989; Marthaler et al,
1999; Heuberger et al, 1998). These effects may worsen the dys-
metabolic syndrome associated with cancer (Tisdale, 1997) and
increase side-effects of chemotherapy, like fatigue (Tisdale, 1997;
Portenoy and Itri, 1999).
Fatigue is a common symptom in patients with advanced cancer
and it frequently occurs after anti-cancer therapies (Stone et al,
2000). In patients with metastatic tumours, cancer-related fatigue
is extremely prevalent and it is observed in 70 to 80% of patients
receiving chemotherapy and up to 90% of radiotherapy patients
(Richardson and Ream, 1996; Morrow et al, 1999; Schwartz et al,
2000). On the basis of current experience, fatigue is considered
primarily treatment-related when there is a clear relationship
between the timing of fatigue and the therapeutic intervention.
In these cases, chemotherapy-induced fatigue is an early side-effect
which peaks within a few days after treatment and declines there-
after (Morrow et al, 1999). Cancer-related fatigue and
chemotherapy-related fatigue are multifactorial, however, anaemia
seems to play a major role (Portenoy and Itri, 1999). Recent
experiences have demonstrated the relationship between mild-
moderate anaemia, fatigue and quality of life (Groopman and Itri,
1999). Treatment of anaemia with epoetin alpha resulted in signif-
icant improvements of energy levels, activity levels, functional
status and overall quality of life (Groopman and Itri, 1999).
Current data suggest that patients with haemoglobin levels 412
gr dl
71 show signiﬁcantly less fatigue and better quality of life than
patients with haemoglobin values less than 12 gr dl
71 (Cleeland et
al, 1999). Epoetins are the mainstay of treatment for anaemia-asso-
ciated fatigue, but other conditions and mechanisms may sustain
fatigue and require a different approach to treatment (Portenoy
and Itri, 1999; Tisdale, 1997). Exercise and education about fatigue
may be beneﬁcial in its relief (Dimeo et al, 1999). Low-dose corti-
costeroids have shown some positive effects against fatigue but data
remain scattered and unconﬁrmed in comparative trials (Portenoy
and Itri, 1999). It was postulated that antidepressant modulating
serotonin may alleviate fatigue in patients treated with chemother-
apy. Unfortunately, the serotonin re-uptake inhibitor paroxetine
was unable to improve fatigue in a double-blind, placebo-
controlled trial (Morrow et al, 2001). Tumour-induced cytokines
and host-produced pro-inﬂammatory cytokines may represent a
possible mechanism contributing to a condition of fatigue. Current
research is exploring these and other mechanisms which could be
the target of future clinical trials for the treatment of fatigue
(McNeil, 2001).
In the present study, a selected population of non-anaemic
patients, with good performance status and without signiﬁcant
comorbidities showed early fatigue after cisplatin or ifosfamide-
based chemotherapy. In the majority of patients, this side-effect
signiﬁcantly improved after LC supplementation which was well
tolerated and did not affect anti-cancer therapeutic efﬁcacy. These
data suggest that chemotherapy-induced damage of the carnitine
system and secondary deﬁciency of the molecule (Dodson et al,
1989; Heuberger et al, 1998; Marthaler et al, 1999; Peluso et al,
2000) may cause fatigue due to impaired energy metabolism (Pelu-
so et al, 2000). It therefore follows that restoration of the carnitine
pool may alleviate this symptom (Brass et al, 2001). To the best of
our knowledge, this is the ﬁrst study which has explored the
therapeutic intervention of the carnitine system for treating
selected patients with chemotherapy-induced fatigue. Results are
encouraging, but these data should be looked at with caution
due to potential biases and limitations inherent to the study itself.
In non-anaemic cancer patients, carnitine deﬁciency may not be
the primary cause of fatigue and concomitant disease-related or
host-related conditions may contribute to this toxicity. Early
chemotherapy-induced asthenia may improve spontaneously and
independently from speciﬁc interventions (Richardson and Ream,
1996; Morrow et al, 1999). Also, reduction of tumour burden in
response to the anticancer treatment may alleviate fatigue. The
urinary excretion of carnitine persists for several days after
chemotherapy and this clearance returns to normal values 7 days
after the administration of cisplatin (Heuberger et al, 1998).
However, even in the presence of carnitine deﬁciency, patients
may restore their carnitine pool by food intake or endogen produc-
tion, and urinary loss may not be sufﬁcient to cause a symptomatic
deﬁciency. Finally, this prospective trial was performed in a popu-
lation of patients with homogenous good physical status, but the
effect of LC supplementation was not compared to a control group
in a randomised fashion.
On the basis of these considerations, present data on LC as an
ergogenic aid after cancer chemotherapy are not compelling.
However, clinical trials which investigate putative therapies against
chemotherapy-induced fatigue are almost lacking (Portenoy and
Itri, 1999), and despite its limitations, the ﬁndings of this early
study are intriguing and open new perspectives for future clinical
trials. Further analyses are required to clarify the potential role
of LC and we are planning to verify the efﬁcacy of this compound
in a randomised, placebo-controlled study.
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